Physician profile
Brandon E Riggan
NPI 1801012042
$2,983.06
in general payments reported to CMS, 2019-2025
31 companies · $960 in 2025
The $960 reported for 2025 was more than what 90% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $239 · 2020: $128 · 2021: $564 · 2022: $442 · 2023: $309 · 2024: $342 · 2025: $960.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,521 · Education: $90.05.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,521.07 |
| Education | $90.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $454.40 | 2019-2024 | Lo Loestrin Fe, Liletta |
| Astellas Pharma US INC | $402.58 | 2023-2025 | Veozah, Myrbetriq |
| Aspira Women'S Health INC | $297.62 | 2021-2024 | Ova1 |
| Biogen, INC. | $214.03 | 2024-2025 | Zurzuvae |
| Bayer Healthcare Pharmaceuticals INC. | $196.80 | 2021-2025 | |
| Coopersurgical, INC. | $174.07 | 2019-2025 | Endosee, Paragard T 380a, Paragard T 380a |
| Exeltis, USA INC. | $162.87 | 2020-2025 | Slynd |
| Organon LLC | $154.84 | 2021-2025 | Nexplanon |
| Hologic Sales and Service, LLC | $100.29 | 2019-2025 | Aptima |
| Merck Sharp & Dohme LLC | $88.46 | 2019-2023 | Gardasil 9 |
| Daiichi Sankyo INC. | $75.98 | 2019-2021 | |
| Millicent US INC | $71.11 | 2025 | Femlyv, Intrarosa, Femring |
| Mylan Pharmaceuticals INC. | $64.97 | 2019-2022 | |
| Sumitomo Pharma America, INC. | $62.96 | 2025 | Myfembree |
| Mayne Pharma Commercial LLC | $60.12 | 2022-2025 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vertex Pharmaceuticals Incorporated | $43.28 | 2024-2025 | |
| Agile Therapeutics, INC. | $42.91 | 2021-2022 | |
| Allergan, INC. | $36.83 | 2019 | |
| Evofem Biosciences, INC. | $35.60 | 2021-2022 | |
| Medtronic, INC. | $28.09 | 2023-2025 | Ligasure, Truclear |
| Shield Therapeutics INC | $26.35 | 2025 | |
| Vertical Pharmaceuticals, LLC | $26.30 | 2019 | |
| Duchesnay USA Incorporated | $25.97 | 2019 | |
| Olympus America INC. | $24.86 | 2025 | Olympus |
| Pfizer INC. | $20.48 | 2023 | |
| Exact Sciences Corporation | $19.59 | 2023 | Cologuard Collection Kit |
| Therapeuticsmd, INC. | $18.67 | 2022 | |
| Scynexis, INC. | $18.41 | 2022 | |
| Lupin INC. | $12.29 | 2020 | |
| Myovant Sciences INC. | $11.17 | 2021 | |
| Avion Pharmaceuticals | $11.16 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brandon Riggan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.